Intracerebral hemorrhage risk factors: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Intracerebral hemorrhage}} {{CMG}}; {{AE}} {{SaraM}} ==Overview== ==Risk factors== ==References== {{reflist|2}} Category:Neurology [[Category:Cardiology]...") |
|||
| Line 7: | Line 7: | ||
==Risk factors== | ==Risk factors== | ||
Common risk factors in the development of [[intracerebral hemorrhage|intracerebral hemorrhage (ICH)]] include:<ref name=Huhtakangas>Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemor- rhage: a longitudinal population-based study. Stroke. 2011;42:2431– 2435. doi: 10.1161/STROKEAHA.111.615260.</ref><ref name=Rådberg> Rådberg JA, Olsson JE, Rådberg CT. Prognostic parameters in sponta- neous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22:571–576. doi: 10.1161/01.STR.22.5.571.</ref><ref name=Flaherty> Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–121. doi: 10.1212/01.wnl.0000250340.05202.8b.</ref> | |||
* [[Hypertension]] | |||
* [[Anticoagulation]] medication | |||
**Vitamin K antagonists (VKAs) such as [[warfarin]] | |||
* Acquired or congenital coagulation factor disorders | |||
**Vitamin K deficiency | |||
**[[Liver disease]] | |||
**[[Disseminated intravascular coagulation|Disseminated Intravascular Coagulation (DIC)]] | |||
**[[Hemophilia]]s | |||
* Acquired qualitative or quantitative platelet abnormalities | |||
* Embolic [[stroke]]s | |||
* [[Sickle Cell Anemia]] | |||
New anticoagulant medications such as [[dabigatran]], [[rivaroxaban]], and [[apixaban]] appear to be associated with a lower risk of ICH than [[vitamin K antagonist|VKA]]s. <ref name=Chatterjee> Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of random- ized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–1490. doi: 10.1001/jamaneurol.2013.4021</ref> | |||
==References== | ==References== | ||
Revision as of 00:57, 24 November 2016
|
Intracerebral hemorrhage Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage (2015) |
|
AHA/ASA Guideline Recommendation for the Primary Prevention of Stroke (2014) |
|
Case Studies |
|
Intracerebral hemorrhage risk factors On the Web |
|
American Roentgen Ray Society Images of Intracerebral hemorrhage risk factors |
|
Risk calculators and risk factors for Intracerebral hemorrhage risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]
Overview
Risk factors
Common risk factors in the development of intracerebral hemorrhage (ICH) include:[1][2][3]
- Hypertension
- Anticoagulation medication
- Vitamin K antagonists (VKAs) such as warfarin
- Acquired or congenital coagulation factor disorders
- Vitamin K deficiency
- Liver disease
- Disseminated Intravascular Coagulation (DIC)
- Hemophilias
- Acquired qualitative or quantitative platelet abnormalities
- Embolic strokes
- Sickle Cell Anemia
New anticoagulant medications such as dabigatran, rivaroxaban, and apixaban appear to be associated with a lower risk of ICH than VKAs. [4]
References
- ↑ Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemor- rhage: a longitudinal population-based study. Stroke. 2011;42:2431– 2435. doi: 10.1161/STROKEAHA.111.615260.
- ↑ Rådberg JA, Olsson JE, Rådberg CT. Prognostic parameters in sponta- neous intracerebral hematomas with special reference to anticoagulant treatment. Stroke. 1991;22:571–576. doi: 10.1161/01.STR.22.5.571.
- ↑ Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–121. doi: 10.1212/01.wnl.0000250340.05202.8b.
- ↑ Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of random- ized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–1490. doi: 10.1001/jamaneurol.2013.4021